Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Eli Lilly and Company (NYSE:LLY – Get Free Report) is expected to issue its quarterly earnings data before the market opens on Thursday, February 6th. Analysts expect the company to announce earnings ...

Eli Lilly and Company's impressive Q4 earnings driven by tirzepatide's success, diverse portfolio, and promising pipeline.

On Thursday, Eli Lilly and Co (NYSE:LLY) stock is trading higher ... partially offset by Zepbound and Humalog. New Products revenue grew by $3.15 billion to $5.64 billion in Q4 2024, led by ...

The company has developed notable medications such as Prozac for depression, Humalog for diabetes, and Mounjaro for type 2 diabetes. Looking closer, Eli Lilly and Company has also outpaced the ...

Six years ago, the average monthly out-of-pocket cost for insulin made by Eli Lilly ... them instead. Lilly, for example, recently revealed that the list price of its Humalog insulin held steady ...

and fast-acting insulin Humalog. And that's before we get into the company's pipeline, which features plenty of investigational drugs beyond Eli Lilly's core area of diabetes and obesity.